Why write ten lines of code when one will do? From magic variable swaps to high-speed data counting, these Python snippets ...

A few years ago, during a taxi ride, the driver described to me how a pig had transformed his life. A childhood with dogs taught him what to expect from animals, yet he was unprepared for the pig he ...

Women gather at a neighborhood square in Lilongwe, Malawi, on June 8 Women gather at a neighborhood square in Lilongwe, Malawi, on June 8Zafer Goder—Anadolu/Getty Images In Malawi, one in three women ...

Exclamation marks, ellipses and ‘haha’ can’t fix our growing inability to communicate. By Nitsuh Abebe “How Many Exclamation Points Are Too Many in an Email? A Psychologist Weighs In.” A psychologist!

This is a review of Truth: What It Is, How To Find It & Why It Still Matters. by Michael Shermer, forthcoming from Johns Hopkins University Press. Amidst claims of “fake news,” “alternative facts,” ...

Dr. Grant, a contributing Opinion writer, is an organizational psychologist at the Wharton School of the University of Pennsylvania. In ancient Greek mythology, a man who falls in love with his own ...

Imre Szenttornyay, CEO of Cielo IT LLC, empowers business owners to scale their operations profitably with AI-powered SmartSigns technology. When you manage a network of retail or franchise locations, ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...